Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

  • Technology appraisal guidance
  • TA276
  • Published: 
Download guidance (PDF)

7 Sources of evidence considered by the Committee

The assessment report for this appraisal was prepared by the School of Health and Related Research (ScHARR):

  • Tappenden P, Harnan S, Uttley L et al., Colistimethate sodium powder and tobramycin powder for inhalation for the treatment of Pseudomonas aeruginosa lung infection in cystic fibrosis, March 2012

The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Manufacturers or sponsors, professional or specialist and patient or carer groups, and other consultees, were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

Manufacturers or sponsors:

  • Forest Laboratories UK

  • Novartis

  • PH&T Pharma

Professional or specialist and patient or carer groups:

  • Cystic Fibrosis Trust

Other consultees:

  • Association of Respiratory Nurse Specialists

  • British Thoracic Society

  • Chartered Society of Physiotherapy

  • Royal College of Nursing

  • Royal College of Paediatrics & Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

  • United Kingdom Clinical Pharmacy Association

  • Department of Health

  • Welsh Government

Commentator organisations (without the right of appeal):

  • British National Formulary

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • Forest Laboratories UK

  • Gilead

  • Novartis

  • Profile Pharma

  • National Institute for Health Research Health Technology Assessment Programme

The following individuals were selected from clinical specialist and patient expert nominations from the non-manufacturer or sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on colistimethate sodium powder and tobramycin powder for inhalation for the treatment of pseudomonas lung infection in cystic fibrosis by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Professor Andrew Greening, nominated by Healthcare Improvement Scotland – clinical specialist

  • Dr Robert Ian Ketchell, nominated by Forest Laboratories UK – clinical specialist

  • Emma Lake, nominated by The Cystic Fibrosis Trust – patient expert

  • Nikki Samsa, nominated by The Cystic Fibrosis Trust – patient expert

Representatives from the following manufacturers or sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy. They were also invited to comment on the ACD.

  • Forest Laboratories UK

  • Novartis